We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+32.34%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$754M
AUM Growth
–
Cap. Flow
+$695M
Cap. Flow %
92.12%
Top 10 Hldgs %
69.88%
Holding
29
New
28
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$89.9M
2
ACHN
Achillion Pharmaceuticals
ACHN
+$56.9M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$46.8M
4
KERX
Keryx Biopharmaceuticals Inc
KERX
+$44.2M
5
NVAX icon
Novavax
NVAX
+$37.2M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 71.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPZM
26
DELISTED
Epizyme, Inc
EPZM
$4.25M 0.56%
+151,000
New +$3.88M
SNMX
27
DELISTED
Senomyx, Inc.
SNMX
$2.13M 0.28%
+975,610
New +$2.01M
OCRX
28
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.27M 0.17%
+225,000
New +$1.4M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for RA Capital Management, which disclosed 29 positions worth $754M. Its ten largest holdings account for 70% of the portfolio.

Its largest position is Acadia Pharmaceuticals: 6,529,810 shares worth $119M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets.

  • RA Capital Management's largest Q2 2013 buy was Acadia Pharmaceuticals: 6,529,810 shares worth $119M.
  • RA Capital Management's ten largest holdings make up 70% of its $754M portfolio in Q2 2013.
  • RA Capital Management disclosed 29 positions in Q2 2013, its first 13F filing on record.

Based on RA Capital Management's 13F filing for Q2 2013, filed 14 Aug 2013.